Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $17.89.

ATEC has been the topic of several research reports. Piper Sandler reaffirmed an "overweight" rating and set a $15.00 price target (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Needham & Company LLC reiterated a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. Wall Street Zen upgraded Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th.

Insiders Place Their Bets

In other Alphatec news, COO Scott Lish sold 55,375 shares of the company's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $13.00, for a total value of $719,875.00. Following the completion of the transaction, the chief operating officer now directly owns 771,645 shares in the company, valued at $10,031,385. This represents a 6.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Sponsel sold 33,732 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $10.83, for a total transaction of $365,317.56. Following the completion of the sale, the executive vice president now owns 668,977 shares in the company, valued at approximately $7,245,020.91. This trade represents a 4.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,798 shares of company stock valued at $1,365,665. Company insiders own 20.90% of the company's stock.

Institutional Trading of Alphatec

Several institutional investors have recently bought and sold shares of the business. Rhumbline Advisers grew its holdings in shares of Alphatec by 6.9% during the first quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company's stock worth $1,508,000 after buying an additional 9,661 shares in the last quarter. Belpointe Asset Management LLC increased its position in shares of Alphatec by 23.3% during the 1st quarter. Belpointe Asset Management LLC now owns 18,500 shares of the medical technology company's stock worth $188,000 after purchasing an additional 3,500 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Alphatec by 18.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company's stock worth $2,696,000 after acquiring an additional 41,264 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Alphatec in the 1st quarter valued at about $257,000. Finally, Parkman Healthcare Partners LLC increased its stake in Alphatec by 95.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 446,106 shares of the medical technology company's stock worth $4,524,000 after buying an additional 217,772 shares during the period. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Trading Up 0.2%

ATEC traded up $0.02 during mid-day trading on Wednesday, hitting $12.46. The stock had a trading volume of 1,418,114 shares, compared to its average volume of 2,042,865. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -9.73 and a beta of 1.06. Alphatec has a 1-year low of $4.88 and a 1-year high of $13.14. The stock's fifty day simple moving average is $11.25 and its 200-day simple moving average is $10.61. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). The business had revenue of $169.18 million during the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm's quarterly revenue was up 22.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.34) earnings per share. As a group, research analysts forecast that Alphatec will post -1.08 EPS for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.